Updated Canadian Rheumatology Association (CRA) Position Statement on Biosimilars

From the Canadian Rheumatology Association (May 21, 2019):

As evidence for the benefits and risks of using biosimilars in the management of rheumatic diseases has grown rapidly, the Canadian Rheumatology Association (CRA) has updated its position statement on biosimilars accordingly. We have undertaken this initiative to ensure that you and your patients are in possession of up-to-date guidance regarding the use and potential benefits and risks of biosimilars so that informed and appropriate treatment decisions may be made.

Please click here to view the updated position statement and FAQ’s.

Note that the CIBRN Leaders will be discussing this updated position policy at the CIBRN webinar to be held Wednesday, May 21 2019. See webinar connection details here.

 

Join the CIBRN Leaders for a webinar on Wednesday, May 22, 9:00 pm ET.

Please join the CIBRN Leaders for Webinar 1 of 2019 on Wednesday, May 22 at 9:00 pm ET. The webinar will review the recent discussions and podcast in the CIBRN community:

  • CIBRN 2019 Q1: Should drug approvals be based on efficacy and demonstrated need, or should pharmacoeconomics be a larger consideration? [View 5 replies to date]
  • CIBRN 2019 Q2: Should manufacturers’ rebates be kept confidential, or should full transparency be expected, in order to more properly compare costs between originators and biosimilars? [View 4 replies to date]
  • CIBRN Podcast Episode 1: Dr. Philip Baer on “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18) [Listen to the podcast]

To connect to the webinar:

Step 1: Join the teleconference at 1-866-830-9434 and enter PIN 7994216

Step 2: Join the web portion by clicking on this link:
https://studio7communications.adobeconnect.com/cibrn_may22_2019/

Listen to CIBRN Podcast Episode 1: Dr. Philip Baer reviews “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18)

Welcome to the CIBRN Podcast channel. This year, we’ve decided to take a fresh approach to article reviews, providing timely and brief (3-5 minutes) podcasts on articles selected and reviewed by CIBRN members. The first in the series has been provided by Dr. Philip Baer.

CIBRN Podcast Episode 1: Dr. Philip Baer on “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18)

Link to reviewed article